Fosgonimeton Phase 1 Trials M3 Biotechnology (later Athira Pharma) completes Phase 1 safety trials of fosgonimeton, a prodrug of Dihexa
50X faster than ICP No complex sample prep needed Results in just 30 minutes Discover XRF advantages: #Pharma #ElementalAnalysis #XRF To view or add a comment, sign in The specialty pharmaceutical market grew from $92.5B in 2023 to $129.2B in 2024, and its upward trajectory is projected to top $965.5B by 2030
Generally, PGC-1 can affect PPCM in three ways: 1) triggering the pro-vascular VEGF-mediated angiogenic signaling
it widens the diameter of blood vessels allowing more blood to be transported through a wider channel and this, in turn, allows more oxygen and nutrients to be delivered to tissues such as the heart or skeletal muscle with exercise
The dual action of Kojic Acid and Glutathione works synergistically to lighten skin pigmentation, including acne scars, dark spots, and age spots